AVAPRO

Compare AVAPRO  to:
Compare
Compare

Generic Name for AVAPRO

Irbesartan 75mg, 150mg, 300mg; tabs.

Legal Classification:

Rx

Pharmacological Class for AVAPRO

Angiotensin II receptor blocker.

Manufacturer of AVAPRO

Bristol-Myers Squibb

Indications for AVAPRO

Hypertension.

Adult dose for AVAPRO

≥16yrs: 150mg once daily; may increase to 300mg once daily. Or, may add a low dose of diuretic. Salt/volume depletion: initially 75mg once daily.

Children's dosing for AVAPRO

Not recommended.

Contraindications for AVAPRO

Pregnancy (Cat.D in 2nd and 3rd trimesters).

Precautions for AVAPRO

Correct salt/volume depletion before beginning therapy, or reduce initial dose. Renal impairment. Severe CHF. Renal artery stenosis. Elderly. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended.

Interactions for AVAPRO

Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes.

Adverse Reactions for AVAPRO

Diarrhea, dyspepsia, fatigue, rhabdomyolysis (rare).

How is AVAPRO supplied?

Tabs 75mg—30, 90
Tabs 150mg, 300mg—30, 90, 500

Related Disease:

Hypertension

Related Resources

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.

Clonidine ER Suspension and Clonidine ER Tablets approved

December 07, 2009

Tris Pharma announced that the FDA has approved Clonidine ER suspension and Clonidine ER tablets, both of which utilize its proprietary OralXR+ platform technology to allow for once daily dosing.

Twynsta approved for the treatment of hypertension

October 19, 2009

The FDA has approved Twynsta (telmisartan/amlodipine tablets, from Boehringer Ingelheim) for the treatment of hypertension alone or in combination with other antihypertensives, or as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals.